Table 3 A summary of available evidence for the association between molecular alterations and IDHi resistance, including the result from the current study.

From: Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia

Implicated mechanisms References
Primary resistance  
 Leukemia stemness Current study
 RUNX1 mutations Current study
 NRAS mutations Amatangelo et al.9, Choe et al.23
 PTPN11 mutations Choe et al.23
 FLT3 mutations (likely) Choe et al.23, current study
Acquired resistance
 Second-site IDH mutations Intlekofer et al.16, Choe et al.23
IDH homolog switch Harding et al.17, Quek et al.15, Choe et al.23, current study
 RTK gene mutations (RAS, FLT3, PTPN11, KIT, and others) Quek et al.15, Choe et al.23, current study
 Differentiation gene mutations (RUNX1, GATA2, and CEBPA) Quek et al.15, Choe et al.23, current study
 TET2 mutations Choe et al.23, current study
 BCOR mutations Quek et al.15, current study